Study identifier:D961DL00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised, double-blind, double-dummy, active-controlled, multicenter study to assess the efficacy and safety of esomeprazole or omeprazole for 5 days in subjects with acute non-variceal upper gastrointestinal bleeding
Gastrointestinal Hemorrhage
Phase 3
No
Esomeprazole IV, Omeprazole IV
All
440
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to assess the efficacy and safety of Esomeprazole and Omeprazole intravenous every 12 hours for 5 days in subjects with acute non-variceal upper gastrointestinal bleeding
Location
Location
Shanghai, China
Location
Beijing, China
Location
Xi’an, Shanxi, China
Location
Wuhan, Hubei, China
Location
Guangzhou, Guangdong, China
Location
Tianjin, China
Location
Fuzhou, Fujian, China
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.